Galdar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galdar

Quick Facts

Property Description
Active Ingredient Letrozole
Form Oral Tablet (Prescription-only)
Pharmacological Class Aromatase Inhibitor (Third-Generation, Nonsteroidal)
General Purpose Provides Systemic Hormonal Therapy (Estrogen Suppression)
Origin Synthetic (Triazole Derivative)

The Core Identity: What Kind of Medicine is Galdar?

Galdar is a prescription-only synthetic antineoplastic agent whose active component is the international non-proprietary name (INN) drug, Letrozole. This medicine is classified as a third-generation nonsteroidal aromatase inhibitor, establishing its position as a highly selective form of hormonal therapy drug intended for systemic use. It is formulated as an oral dosage form tablet.

The Letrozole compound, a triazole derivative, possesses higher potency compared to earlier inhibitors, differentiating it as a totally selective agent. This highly targeted approach is designed to produce profound hormonal effects while minimizing interaction with other vital steroidogenic pathways.

Composition and Mechanism: How Letrozole Achieves Selective Estrogen Suppression

Galdar is a single-ingredient product reliant exclusively on the activity of Letrozole. Its primary pharmacological action centers on the selective enzyme blockade of the aromatase enzyme system. The mechanism works by competitively binding to the enzyme, thereby preventing the conversion of precursor hormones (androgens) into active estrogens.

This targeted inhibition leads to a significant reduction—or suppression—of circulating estrogen levels in the body, which is the desired outcome of the therapy. This action is associated with achieving near-complete aromatase inhibition, an effect central to its therapeutic utility.

General Therapeutic Purpose: The Benefit of Hormone Suppression

The overall purpose of Galdar is to provide highly effective systemic hormonal therapy by dramatically limiting the body's estrogen supply. This principle is especially relevant for patient groups such as postmenopausal women, where peripheral tissue becomes the primary site of estrogen production.

By achieving sustained estrogen suppression, the medicine helps control the growth and progression of certain cellular activities that are known to be hormone-sensitive. This targeted reduction in estrogen levels is the central function of the drug in hormone receptor-positive therapeutic settings.

Regulatory References

  1. Letrozole - NCI - National Cancer Institute

What side effects are possible with Galdar?

The safety profile of Galdar (Letrozole) is officially documented by government regulatory agencies, classifying potential adverse reactions by frequency and the organ systems affected.

Official Adverse Reaction Classification

Adverse effects are categorized based on their incidence in clinical studies. Very Common reactions (occurring in 10% or more of patients) include hot flashes, arthralgia (joint pain), and fatigue. Common reactions (occurring in 1% to 10%) include headache, dizziness, nausea, increased sweating, hypertension, and edema (swelling).

Reactions are grouped into system-organ classes, with major documented effects including Musculoskeletal and Connective Tissue Disorders (e.g., bone pain and osteoporosis) and Metabolism and Nutrition Disorders (e.g., hypercholesterolemia).

Serious Safety Considerations

The most clinically significant risks highlighted in regulatory warnings relate to long-term effects on bone health, specifically decreases in Bone Mineral Density (BMD), leading to an increased risk of osteoporosis and bone fractures with prolonged use. An increase in total serum cholesterol is also a documented concern requiring monitoring. Based on official reports, the medicine is contraindicated in women who are or may become pregnant due to the potential for embryo-fetal toxicity.

Population-Specific Safety Notes

The label specifies that patients with severe hepatic impairment (severe liver disease) should be kept under close supervision due to the potential for doubled systemic drug exposure. Due to reports of dizziness and somnolence, regulatory documents advise caution regarding activities that require mental alertness.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the required steps and known risks associated with an overdosage of Galdar, focusing strictly on management and documented manifestations.

Immediate medical attention is necessary upon the recognition of any signs, symptoms, or complications suggestive of overdosage.

Overdose Manifestations Description (Based on Regulatory Labeling)
Documented Presentations Includes all signs, symptoms, and laboratory findings associated with overdosage from available human data, such as accidental intake or acute ingestion.
Life-Threatening Risks Identification of potential severe outcomes, organ toxicity, or delayed effects that require urgent intervention, including the dose amount considered life-threatening if specified in labeling.
Emergency Procedures Standard general treatment measures and specific steps for maintaining vital functions, such as patient monitoring and symptomatic support.
Antidote or Management Administration of a proven antidote, if one is officially available and specified in the label, or instructions for enhanced elimination procedures (e.g., use of activated charcoal).

All supportive measures for an overdose must follow the specific instructions and monitoring requirements outlined in the authorized prescribing information. Patients must be closely observed for any severe or prolonged effects as described in the official overdose profile.

Therapeutic Uses of Galdar

Galdar is a component of systemic hormonal therapy used for hormone receptor-positive breast cancer in postmenopausal women. Its therapeutic use includes a focus on controlling disease growth and reducing recurrence risk. This medication is commonly used to manage the risk of recurrence in early-stage disease, as an extended treatment after initial therapy, and to address advanced or metastatic presentations.

Therapeutic Scenarios and Benefits

In the early stage, Galdar contributes to improving the patient’s disease-free survival following primary treatment. This is considered relevant because hormonal therapy plays a role in managing the risk of cancer recurrence in the adjuvant setting. This application supports the long-term goal of reducing the chance of the cancer returning locally or spreading. For advanced or metastatic presentations, Galdar is commonly used to help with advanced or metastatic breast cancer. For patients whose tumors remain sensitive to hormones, the practical benefit may assist with maintaining disease stabilization or supporting measurable tumor reduction. This assists with managing the rate of disease progression and contributes to easing the overall symptom load during periods of heightened symptoms.


Quick Fact: Therapeutic Focus on Systemic Recurrence This medication is applied in addressing the risk of recurrence and disease progression in patients whose tumors are fueled by circulating hormones. Its benefit is generally focused on long-term disease control.

Eligibility and Restrictions for Use

Galdar (galantamine) is an acetylcholinesterase inhibitor primarily prescribed for the treatment of mild to moderate dementia of the Alzheimer's type. It is typically used in adult patients who have a confirmed diagnosis of Alzheimer’s disease.


Contraindications

The use of Galdar is not recommended in several patient groups, primarily due to the risk of increased side effects or complications. These include:

  • Hypersensitivity or Allergy: Patients with a known allergy to galantamine or any component of the formulation.
  • Severe Organ Impairment: Individuals with severe liver disease (Child-Pugh Class C) or severe kidney disease (creatinine clearance less than 9 mL/min).
  • Recent Gastrointestinal Surgery: Patients with a recent history of stomach or bowel surgery, or those with a complete stomach blockage.

Need for Caution and Medical Review

Patients with certain other medical conditions require careful monitoring, as Galdar may exacerbate their symptoms or increase the risk of serious side effects. These conditions include:

Condition
History of severe asthma or other obstructive lung disease
Heart rhythm problems (e.g., bradycardia, heart block)
History of seizures or epilepsy
Active stomach or duodenal ulcers or a history of stomach bleeding
Urinary bladder outflow obstruction
Moderate liver or kidney impairment

It is essential to inform your healthcare provider of your complete medical history before starting treatment with Galdar. Use in the pediatric population for Alzheimer's disease has not been established.

What should I know about interactions with other medicines?

Galdar Interactions with other medicines and products

This section summarizes the official information regarding how other medicines, foods, or products may affect Galdar in the body, or how Galdar may affect them. Official regulatory documentation requires the identification of clinically significant drug-drug, drug-food, and drug-supplement interactions.

Interactions with Other Medicinal Products

Interaction Scope Description in Official Documents
Drug Metabolizing Enzyme Inhibitors Co-administration with strong inhibitors of primary drug-metabolizing enzymes (e.g., certain CYP450 enzyme inhibitors) may increase the concentration of Galdar in the bloodstream. This typically requires regulatory guidance to either avoid the combination or monitor closely, often resulting in a change to the dose of Galdar or the interacting medicine.
Drug Metabolizing Enzyme Inducers Co-administration with strong inducers of primary drug-metabolizing enzymes may decrease the concentration of Galdar in the bloodstream, potentially reducing its overall effectiveness. Regulatory documents specify that such combinations may need to be avoided or require a dose increase of Galdar.
Drug Transport System Modulators Interactions with medicines that inhibit or induce drug transport systems (e.g., P-glycoprotein) are officially documented if they significantly alter the absorption or distribution of Galdar in the body.

Food and Specific Product Interactions

Official labeling addresses interactions with food and beverages that can alter drug absorption or metabolism. For example, the consumption of certain fruit juices, such as grapefruit juice, can inhibit specific metabolic enzymes, leading to altered drug concentrations, which regulatory agencies classify as a potentially clinically significant interaction requiring specific warnings. Specific Galdar labeling would detail any such constraints.

Mechanism of Action

The mechanism of Galdar (Letrozole) is defined by its ability to profoundly and selectively alter the Steroidogenesis pathway by targeting a single, essential enzyme.


Selective Inhibition of the Aromatase Enzyme

Galdar functions as a nonsteroidal competitive inhibitor that targets the Aromatase enzyme ( CYP19A1), the key molecular structure responsible for the final conversion of Androgens into Estrogens ( Estradiol). This interaction immediately initiates the mechanistic cascade by blocking the enzyme's catalytic site, which leads to a rapid cessation of Estrogen synthesis, primarily within peripheral tissues.


Profound Systemic Estrogen Suppression

The consequence of this targeted enzyme blockade is systemic Estrogen deprivation, establishing a sustained state of extremely low circulating Estradiol levels (typically >90% suppression). This profound physiological adjustment eliminates the Estrogen-dependent signal for cellular activity, which is the core action shaping the drug's overall physiological impact.


Modulation of Hormonal Feedback and Mechanism Limits

The drug's suppression of Estrogen indirectly affects the Hypothalamic- Pituitary- Gonadal ( HPG) axis by removing Estrogen's negative feedback, resulting in a compensatory increase of LH and FSH. This feedback mechanism acts as a physiological constraint: in biological contexts where ovaries are fully functional, this gonadotropin surge can override the drug’s peripheral inhibition, resulting in failure to achieve systemic Estrogen deprivation.

Dosage and Administration Information

Administration Guidelines for Galdar (Letrozole)

Galdar is a medicine with a standardized usage protocol, ensuring consistency across its therapeutic uses. The following guidelines describe standard administration and dosage parameters for this medication.


Administration Scope and Dosing

Feature Instruction
Route of Administration Oral (by mouth)
Standard Daily Dose 2.5 mg once daily for all approved indications.
Intake Instructions Swallow the tablet whole; do not crush or chew.
With or Without Food The tablet may be taken with or without food.

Duration and Special Conditions

Feature Instruction
Treatment Duration For early-stage use, treatment is typically continued for 5 years or until tumor recurrence. For advanced disease, treatment continues until disease progression is observed.
Older Adults No dose adjustment is required.
Renal Impairment No dose adjustment is required for patients with greater than or equal to 10 mL/min creatinine clearance.
Severe Hepatic Impairment A reduced dose of 2.5 mg every other day is recommended for patients with cirrhosis and severe liver dysfunction.

Procedural Structure

As part of the established protocol, Galdar is taken at the same time each day. If a dose is missed, it is typically taken as soon as remembered, unless the next dose is due within a few hours (e.g., 2–3 hours), in which case the missed dose is skipped; a double dose is not taken to compensate. This protocol establishes a continuous, long-term oral regimen followed as prescribed.

Recent Clinical Evidence

Galdar (galantamine) is a medication approved for the symptomatic treatment of mild to moderate dementia of the Alzheimer's type. Its clinical effectiveness is based on its dual mechanism of action: as a reversible cholinesterase inhibitor and as a positive allosteric modulator of neuronal nicotinic acetylcholine receptors.

Efficacy in Mild to Moderate Alzheimer's Disease

Clinical trials have consistently demonstrated that Galdar provides a statistically significant benefit over placebo in measures of cognition and function in patients with mild to moderate Alzheimer's disease. Key studies, including large, multinational, randomized, placebo-controlled trials, have shown that patients treated with Galdar experience improvements or a slower rate of decline in standardized cognitive scales, such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and in functional scales measuring activities of daily living.

Clinical Outcome Demonstrated Effect in Trials
Cognition (e.g., Memory, Language) Significant improvement or delayed decline vs. placebo
Function (Activities of Daily Living) Maintained function or delayed decline vs. placebo
Behavioral Symptoms No consistent significant effect on all behavioral symptoms, but some benefit reported for apathy

Safety and Tolerability Profile

The most frequently reported adverse events associated with Galdar are typically gastrointestinal in nature, reflecting its cholinergic mechanism of action. These include nausea, vomiting, diarrhea, and abdominal pain. These side effects are generally most common during the initiation of treatment and dose escalation and tend to be mitigated by starting at a low dose and increasing gradually, as well as taking the medication with food. Other common side effects include headache and dizziness. Serious adverse events, such as bradycardia (slow heart rate) and syncope (fainting), have been reported but are less common. Clinical evidence supports that Galdar is generally well-tolerated when administered according to established dosing guidelines.

Frequently Asked Questions (FAQ)

Common questions about Galdar (FAQ)

Q: What is Galdar actually used for, besides the main thing?

A: Galdar is used for different conditions based on its active ingredient. Official documents state Galdar (Letrozole) is indicated for several types of hormone receptor-positive breast cancer. Separately, Galdar (Galantamine) is officially approved for the symptomatic treatment of mild to moderate dementia of the Alzheimer's type.


Q: Is Galdar a steroid or an antibiotic?

A: No, Galdar is neither a steroid nor an antibiotic. Regulatory agencies classify the Letrozole component of Galdar as a non-steroidal aromatase inhibitor, and the Galantamine component as a reversible cholinesterase inhibitor.


Q: Does Galdar cause weight gain or weight loss?

A: Official reports indicate varying effects depending on the active ingredient. Letrozole commonly causes increased weight (weight gain) as an adverse reaction. Conversely, Galantamine commonly causes decreased weight (weight loss).


Q: Is it normal to feel a bit dizzy in the first few days on Galdar?

A: Dizziness is listed in official product information as a common adverse reaction for both active components of Galdar. Regulatory documents indicate that adverse reactions are typically most common during the treatment initiation and dose-escalation phases.


Q: Can Galdar mess up your sleep schedule?

A: Official product information for Galdar (Galantamine) reports side effects including somnolence (drowsiness) and insomnia (trouble sleeping). Galdar (Letrozole) also lists general fatigue and somnolence as adverse effects.


Q: Are there any common over-the-counter medicines I should avoid while taking Galdar?

A: Official warnings note that Galantamine requires careful monitoring when taken with nonsteroidal anti-inflammatory drugs (NSAIDs) due to an increased risk of gastrointestinal bleeding. Letrozole interactions are generally described by enzyme inhibitor/inducer classification. Regulatory documents advise discussing all medications, including over-the-counter products, with a healthcare provider due to the potential for interactions.


Q: How long does Galdar stay in your system after you stop taking it?

A: The time a medication remains in the body is linked to its half-life. The reported terminal elimination half-life is approximately two days for Letrozole and about seven hours for Galantamine. Complete clearance occurs over multiple half-lives.


Q: Does Galdar interact with birth control pills?

A: Regulatory documents indicate that Letrozole may interact with medicines that induce or inhibit primary drug-metabolizing enzymes. Galantamine interacts with anticholinergic agents. Official documentation advises discussing all medications, including hormonal contraceptives, with a healthcare provider due to the potential for interactions based on effects on enzyme systems.


Q: Is Galdar available as a generic version?

A: Regulatory documents confirm that both active components of Galdar, Letrozole and Galantamine Hydrobromide, are available under different brand names and also in generic versions, depending on the region and manufacturer.


Q: Can children or teenagers take Galdar?

A: Official documents state that the safety and effectiveness of Galantamine have not been established in pediatric patients. For Letrozole, official labeling includes information on use in children; however, decisions about its use are based on the specific medical condition.


Q: What are the long-term side effects that people worry about with Galdar?

A: For Letrozole, long-term use is associated with clinically significant documented risks, including a decrease in bone mineral density which can lead to osteoporosis and fractures, and increased total serum cholesterol. Long-term use of Galantamine requires regular monitoring of weight and cardiovascular status, as noted in official reports.


Q: Has Galdar been around for a long time, or is it a newer drug?

A: According to regulatory approval history, the active components of Galdar have been available for several years. Letrozole received its initial FDA approval in 1997, and Galantamine received its initial FDA approval in 2001.


Q: What should I do if the side effects of Galdar feel too strong?

A: Official patient counseling information advises contacting a healthcare provider right away if severe or serious side effects, or symptoms of an overdose, are experienced. This ensures prompt guidance based on individual health status.


Q: Can Galdar cause any problems with your skin?

A: Yes, official adverse reaction reports confirm that Letrozole can cause common side effects such as rash and pruritus (itching), with rare reports of severe skin reactions. Galantamine has also been associated with rare but serious skin reactions, including Stevens-Johnson syndrome.


Q: Does Galdar interact with common supplements like Vitamin D or fish oil?

A: Official documentation encourages patients to discuss all medications and supplements they use, including vitamins and herbal products, with a healthcare provider. This is because specific interactions, although not always detailed in general warnings, could occur.


Q: Is it true that Galdar can cause mood swings or anxiety?

A: Yes, official side effect listings confirm that changes in mood are possible. Letrozole has been associated with less common side effects including mental depression and anxiety. Galantamine has reported common side effects including depression and nervousness.


Q: Will Galdar interfere with having a surgery or procedure soon?

A: Galantamine, as a cholinesterase inhibitor, may intensify the effects of certain neuromuscular blocking agents used during surgical anesthesia. Discussion with the medical team about all current medications prior to any procedure is recommended in regulatory documents.


Q: Are there any specific foods to absolutely avoid while taking Galdar?

A: Regulatory documents highlight that consuming grapefruit juice can inhibit specific metabolic enzymes, which may alter drug concentrations and require specific warnings. Aside from this, the medication is generally permitted to be taken with or without food.


Q: Does Galdar affect fertility in men or women?

A: Letrozole is officially noted as being potentially toxic to the embryo or fetus and is contraindicated in women who are or may become pregnant. In nonclinical animal studies, Galantamine did not show evidence of impairing fertility.


Q: Why might a doctor prescribe Galdar for an elderly patient?

A: Official guidance states that no dose adjustment is required for older adults taking Letrozole, based on age alone. Galantamine is specifically approved for the treatment of Alzheimer's disease, which primarily affects the elderly population.


Q: Is Galdar commonly used in other countries?

A: Yes, the active ingredients in Galdar, Letrozole and Galantamine, are approved and widely used under various trade names in countries regulated by major international health authorities, including those in Europe and North America.


Q: Does Galdar interact with alcohol, and how bad is it?

A: Official product information advises that Galantamine should not be taken with alcohol. General warnings note that interaction may occur with both active ingredients and recommend discussing the use of alcohol with a healthcare provider.


Q: Do I need to get blood tests done regularly while taking Galdar?

A: Yes, regulatory warnings note that patients taking Letrozole may require regular monitoring of total serum cholesterol and bone mineral density. Patients taking Galantamine may also require weight monitoring.


Q: What should I know about Galdar if I have a history of liver problems?

A: Official regulatory documents contain specific guidance for liver impairment. Galantamine use is not recommended for patients with severe liver disease. For Letrozole, a reduced dose is recommended for patients with severe hepatic (liver) impairment.


Q: Is it okay to take Galdar if I have high cholesterol?

A: Official warnings state that Letrozole can increase cholesterol levels. Therefore, its use requires caution and monitoring in patients who have pre-existing high cholesterol levels.

How should Galdar be stored and disposed of?

Storage and Environmental Control

Galdar (Letrozole) tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted short excursions between 15 C and 30 C (59 F and 86 F). The medicine must be kept away from excess heat, moisture, and direct light, and must not be frozen.

Packaging and Child Safety

The product must remain in its original container and be kept tightly closed to protect its integrity. It is an explicit regulatory requirement that Galdar must be stored out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Do not use this medicine after the expiry date shown on the carton. Unused or expired Galdar must not be thrown away via wastewater or household waste to help protect the environment. Disposal should follow the guidance of a healthcare professional or pharmacist, typically by utilizing a drug take-back program or specialized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Galdar found in:

A-Z Index: